The latest research results of camrelizumab neoadjuvant therapy for esophageal cancer were selected for oral presentation at the 2022 AATS annual meeting

SHANGHAI, May 17, 2022 /PRNewswire/ -- From May 14 to 17, 2022, the 102nd annual meeting of the American Association for Thoracic Surgery (AATS) was held in Boston, U.

AATS oral presentation

The American Association for Thoracic Surgery (AATS) annual meeting is the world's largest and highest academic conference in the field of cardiothoracic surge.

Esophageal cancer is a high-incidence malignant tumor in China, and about 190,000 patients die of esophageal cancer every year [

The ESPRIT study is a single-arm, prospective, phase II clinical study of camrelizumab combined with paclitaxel and nedaplatin in the neoadjuvant treatment of locally advanced esophageal squamous cell carcino.

According to Professor Ma Jianqun, the principal investigator of the ESPRIT study and the Affiliated Cancer Hospital of Harbin Medical University, "The phased results of the ESPRIT study give us great encouragement, which is of great significance for prolonging the survival time of patients with esophageal cancer and improving the prognosis of patien.

The ESPRIT study is a phase II clinical study led by the esophagus-mediastinum ward of the Thoracic Surgery Department of Harbin Medical University Cancer Hospit.

Camrelizumab is a humanized PD-1 monoclonal antibody independently developed by China's national innovative pharmaceutical company Hengrui Medicine and has intellectual property righ.

Professor Ma Jianqun

Ma Jianqun, Chief Physician Professor Postdoctoral Doctor of Medicine Doctoral Supervisor

Director of Esophageal Mediastinal Ward, Thoracic Surgery Department, Cancer Hospital Affiliated to Harbin Medical University

Member of the Standing Committee of the Mediastinal Tumor Professional Committee of the Chinese Anti-Cancer Association

Standing Committee Member of Esophageal Cancer Professional Committee of China Anti-Cancer Association

Standing member of the Chinese Society of Clinical Oncology (CSCO) Mediastinal Tumor Expert Committee

Standing member of the Chinese Society of Clinical Oncology (CSCO) Esophageal Cancer Expert Committee

The fifth editorial board of "Chinese Journal of Lung Cancer"

Editorial Board Member of AME Press Mediastinum Magazine

Head of Heilongjiang Provincial Branch of National Esophageal Cancer Clinical Research Center

Director of Heilongjiang Anti-Cancer Association

Head of Heilongjiang Esophageal Cancer Diagnosis and Treatment Center

Head of Heilongjiang Province Esophageal Cancer Mediastinal Tumor Specialist Alliance

Chairman of the Professional Committee of Esophageal Cancer of Heilongjiang Medical Association

Chairman of the Esophageal Cancer Professional Committee of Heilongjiang Anti-Cancer Association

Vice Chairman Committee of Thoracic Oncology Professional Committee of Heilongjiang Medical Association

Deputy Chairman of the Mediastinal Tumor Professional Committee of Heilongjiang Medical Association

Vice Chairman of Thoracic Surgery Branch of Heilongjiang Medical and Healthcare International Exchange Promotion Association

Deputy Head of Thoracic Surgery Group, Medical Robot Branch of Heilongjiang Medical Association

Specialist visit time: every Saturday and Monday morni.

references

[1] Chen W, Zheng R, Baade PD, et .

[2] Malhotra GK, Yanala U, Ravipati A, et .

[3] Ma J, Zhang J, Yang Y, et .

[4] Davies.

[5] Luo H, Lu J, Bai Y, et .

Source: Jiangsu Hengrui Pharmaceutical .